Abstract 588P
Background
HER2 alterations in non-small cell lung cancer (NSCLC) are recognized as challenging therapeutic targets with unmet clinical needs. While the recent advent of HER2 ADC has shown some clinical benefits, its efficacy in real-world clinical settings remains largely uncharted. Thus, we conducted a multi-center retrospective study to assess the efficacy of HER2 ADC in a real-world context.
Methods
We continuously enrolled patients with ERBB2-altered NSCLC who underwent monotherapy or combination therapy with Disitamab Vedotin (RC48) between August 2021 and March 2023.
Results
A total of 22 patients with HER2 alterations were enrolled, including 15 with HER2 mutations, 5 with HER2 amplifications, and 2 with both. The overall objective response rate (ORR) was 45.5% (10/22), disease control rate (DCR) was 90.9% (20/22), and median progression-free survival (mPFS) stood at 7.5 months (95% CI 6.6-8.4 months). 95.5% of patients (21/22) underwent combination therapy, yielding an ORR of 47.6% (10/21). Combination regimens includes platinum, anti-angiogenesis, HER2 TKIs, and PD-1/PD-L1 inhibitors. Of note, the platinum-based combination regimen shows the highest ORR at 71.4% (5/7), following is HER2-TKI at 50% (4/8). First-line treatment patients experienced an ORR of 62.5% (5/8), whereas second-line and third-line or beyond treatments demonstrated ORRs of 57.1% (4/7) and 14.3% (1/7) respectively. No significant difference in mPFS was observed between 1L and 2L or subsequent treatments. The mPFS was notably prolonged in HER2-amplified patients and anti-HER2 naïve patients.
Conclusions
For HER2-altered NSCLC patients, RC48 combined therapies are applicable treatment options, particularly with platinum agents. RC48 combined therapies also offers a new treatment approach for patients with HER2 amplification.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
570P - First-line osimertinib for patients with advanced NSCLC harboring EGFR mutations: A real-world study
Presenter: Wenxiang Ji
Session: Poster Display
Resources:
Abstract
571P - Dacomitinib in treatment-naïve EGFR-mutant NSCLC patients with multiple brain metastases: Initial efficacy and safety data from a phase II study
Presenter: Yongfeng Yu
Session: Poster Display
Resources:
Abstract
572P - Multivariable five-year survival prediction model for prognosing patients with EGFR-mutated NSCLC treated with EGFR-TKIs
Presenter: Qi-An Wang
Session: Poster Display
Resources:
Abstract
573P - LUMINATE-103: Real-world treatment patterns and outcomes of patients (pts) with epidermal growth factor receptor mutant (EGFR MU), non-squamous (NSQ) locally advanced/metastatic non-small cell lung cancer (a/mNSCLC): Pooled analysis of large US electronic health record (EHR) datasets
Presenter: Byoung Chul Cho
Session: Poster Display
Resources:
Abstract
574P - Efficacy and safety of dacomitinib in treatment-naïve patients with advanced NSCLC harboring uncommon EGFR mutations
Presenter: Lin Wu
Session: Poster Display
Resources:
Abstract
575P - Efficacy and safety of dacomitinib in treatment-naïve patients with advanced NSCLC and brain metastasis: A multicenter cohort study
Presenter: Puyuan Xing
Session: Poster Display
Resources:
Abstract
576P - Clonality of both EGFR and co-occurring TP53 mutations affect the treatment efficacy of the third-generation EGFR-TKIs in advanced-stage EGFR-mutant non-small cell lung cancer
Presenter: Wen Feng Fang
Session: Poster Display
Resources:
Abstract
577P - A study of the efficacy and safety of amivantamab in EGFR exon 20 insertion (E20I) mutations in NSCLC
Presenter: Daeho Choi
Session: Poster Display
Resources:
Abstract
578P - Tyrosine kinase inhibitor treatment of elderly patients with epidermal growth factor receptor mutated advanced non-small cell lung cancer: A multi-institute retrospective study
Presenter: Ling-Jen Hung
Session: Poster Display
Resources:
Abstract
579P - Real-world study of dacomitinib as first-line treatment for patients with EGFR-mutant non-small cell lung cancer
Presenter: Ji Eun Shin
Session: Poster Display
Resources:
Abstract